We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

064350:KRXHyundai Rotem Company Analysis

Data as of 2026-03-13 - not real-time

₩198,500.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Hyundai Rotem trades at KRW 198,500, well above its DCF fair value of roughly KRW 140,000, suggesting the stock is currently overvalued despite a forward P/E of 14.9 that is less than half the industry average of 29.1. Revenue is expanding at a healthy 12.8% rate and the company delivers strong profitability metrics, with a gross margin of 23.8%, operating margin of 16.5% and a ROE of 30.5%, underscoring robust operational efficiency. The balance sheet is solid, featuring ample cash of KRW 1.28 trillion against modest debt, and a payout ratio of just 3.2% supports the dividend’s sustainability.
Technical signals are mixed: the price sits above the 20‑day and 50‑day SMAs, confirming a bullish trend, yet the MACD histogram is deep in negative territory and the RSI at 44 indicates neutral momentum, while volume is on an upward trajectory. These dynamics, combined with high 30‑day volatility (≈96%) and a low beta, point to a stock that can swing sharply but is less correlated with broader market moves, shaping a moderate overall risk profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 5/10

Key Factors

  • bearish MACD histogram indicating short‑term downside pressure
  • RSI near the neutral zone (44) suggesting limited upside momentum
  • price approaching recent support level around KRW 195,100

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • solid revenue growth of 12.8% and high ROE of 30.5%
  • forward P/E well below industry average, implying relative undervaluation
  • strong cash generation and low debt enhancing financial flexibility

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • diversified exposure to rail, defense and hydrogen mobility sectors
  • sustainable dividend backed by low payout ratio and robust cash flow
  • overvalued market price relative to DCF limiting long‑term upside

Key Metrics & Analysis

Financial Health

Revenue Growth12.80%
Profit Margin13.19%
P/E Ratio14.9
ROE30.51%
ROA8.61%
Debt/Equity4.35
Op. Cash Flow₩904.3B
Free Cash Flow₩609.7B
Industry P/E29.1

Technical Analysis

TrendBullish
RSI43.9
Support₩195,100.00
Resistance₩274,000.00
MA 20₩214,775.00
MA 50₩212,920.00
MA 200₩197,004.50
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Fair Value₩140,392.98
Target Price₩301,578.94
Upside/Downside51.93%
GradeOvervalued
TypeGrowth
Dividend Yield0.30%

Risk Assessment

Beta0.20
Volatility96.22%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.